Payment overview · 2025
General Payments
$136,439.88
119 reported records · 22 companies
Healthcare provider profile · identity verified
Amber M Shane, DPM
Podiatric Medicine & Surgery Service Providers|Podiatrist|Foot & Ankle Surgery · ORLANDO, FL · NPI 1013967249
Verified facts
What the public records show
CMS Open Payments records show Amber M Shane, DPM received $136,439.88 in general payments during 2025 across 119 reported records.
TREACE MEDICAL CONCEPTS, INC. accounted for 91.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 57 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuzyra.
Paratek Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUZYRA as an associated drug or biological on 24089 records involving 10216 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuzyra by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $124,837.59 | 91.5% | 43 | 2025 |
| Paragon 28, Inc. | Unresolved — no canonical attribution shown | $5,906.24 | 4.3% | 9 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $4,630.55 | 3.4% | 8 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $169.90 | 0.1% | 18 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $143.91 | 0.1% | 8 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $141.57 | 0.1% | 14 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $137.80 | 0.1% | 1 | 2025 |
| restor3d, inc. | Unresolved — no canonical attribution shown | $126.39 | 0.1% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $38.96 | 0.0% | 2 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $35.11 | 0.0% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $30.25 | 0.0% | 2 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $29.54 | 0.0% | 1 | 2025 |
| Access Pro Medical, LLC | Unresolved — no canonical attribution shown | $26.94 | 0.0% | 1 | 2025 |
| ACUMED LLC | Unresolved — no canonical attribution shown | $24.76 | 0.0% | 1 | 2025 |
| Dynasplint Systems Inc. | Unresolved — no canonical attribution shown | $24.30 | 0.0% | 1 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $22.65 | 0.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.23 | 0.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.58 | 0.0% | 1 | 2025 |
| Surgenex LLC | Unresolved — no canonical attribution shown | $20.22 | 0.0% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $17.84 | 0.0% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $17.54 | 0.0% | 1 | 2025 |
| Sanara MedTech Inc. | Unresolved — no canonical attribution shown | $16.01 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Royalty or License | $83,765.00 | 13 |
| Consulting Fee | $45,613.13 | 16 |
| Travel and Lodging | $5,083.89 | 17 |
| Food and Beverage | $1,977.86 | 73 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LAPIPLASTY SYSTEM 1 Normalized: lapiplasty system 1 |
Device | TREACE MEDICAL CONCEPTS, INC. | $123,556.84 | 32 | 2025 |
Source payment records
|
|||||
| Portfolio Normalized: portfolio |
Device | Paragon 28, Inc. | $5,596.36 | 7 | 2025 |
Source payment records
|
|||||
| PROSTEP Normalized: prostep |
Device | Stryker Corporation | $2,750.00 | 2 | 2025 |
Source payment records
|
|||||
| AXSOS Normalized: axsos |
Device | Stryker Corporation | $2,500.00 | 3 | 2025 |
Source payment records
|
|||||
| INBONE Normalized: inbone |
Device | Stryker Corporation | $2,500.00 | 3 | 2025 |
Source payment records
|
|||||
| T2 Normalized: t2 |
Device | Stryker Corporation | $2,500.00 | 3 | 2025 |
Source payment records
|
|||||
| ORTHOLOC 3DI Normalized: ortholoc 3di |
Device | Stryker Corporation | $2,003.73 | 2 | 2025 |
Source payment records
|
|||||
| ANCHORAGE Normalized: anchorage |
Device | Stryker Corporation | $2,000.00 | 1 | 2025 |
Source payment records
|
|||||
| ASNIS Normalized: asnis |
Device | Stryker Corporation | $2,000.00 | 1 | 2025 |
Source payment records
|
|||||
| PROSTEP MICA Normalized: prostep mica |
Device | Stryker Corporation | $2,000.00 | 1 | 2025 |
Source payment records
|
|||||
| GAMMA Normalized: gamma |
Device | Stryker Corporation | $1,750.00 | 2 | 2025 |
Source payment records
|
|||||
| VARIAX Normalized: variax |
Device | Stryker Corporation | $1,750.00 | 2 | 2025 |
Source payment records
|
|||||
| HOFFMANN Normalized: hoffmann |
Device | Stryker Corporation | $750.00 | 1 | 2025 |
Source payment records
|
|||||
| LAPIPLASTY Normalized: lapiplasty |
Device | TREACE MEDICAL CONCEPTS, INC. | $415.90 | 2 | 2025 |
Source payment records
|
|||||
| CUT GUIDE Normalized: cut guide |
Device | TREACE MEDICAL CONCEPTS, INC. | $379.79 | 2 | 2025 |
Source payment records
|
|||||
| Monkey Bars Normalized: monkey bars |
Device | Paragon 28, Inc. | $257.09 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $169.90 | 18 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $137.80 | 1 | 2025 |
Source payment records
|
|||||
| TMC NANOPLASTY SYSTEM Normalized: tmc nanoplasty system |
Device | TREACE MEDICAL CONCEPTS, INC. | $134.39 | 3 | 2025 |
Source payment records
|
|||||
| HEALIX KNOTLESS PEEK Normalized: healix knotless peek |
Device | DePuy Synthes Sales Inc. | $87.84 | 8 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $84.85 | 5 | 2025 |
Source payment records
|
|||||
| DYNATAPE Normalized: dynatape |
Device | DePuy Synthes Sales Inc. | $83.18 | 10 | 2025 |
Source payment records
|
|||||
| PERCUPLASTY TRAY Normalized: percuplasty tray |
Device | TREACE MEDICAL CONCEPTS, INC. | $81.78 | 2 | 2025 |
Source payment records
|
|||||
| Monkey Rings Normalized: monkey rings |
Device | Paragon 28, Inc. | $52.79 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY ADAPTIS Normalized: infinity adaptis |
Device | Stryker Corporation | $52.35 | 1 | 2025 |
Source payment records
|
|||||
| DYNACORD Normalized: dynacord |
Device | DePuy Synthes Sales Inc. | $52.08 | 4 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| AUGMENT INJECTABLE Normalized: augment injectable |
Device | Stryker Corporation | $38.26 | 1 | 2025 |
Source payment records
|
|||||
| CITREFIX Normalized: citrefix |
Device | Stryker Corporation | $36.21 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $35.11 | 2 | 2025 |
Source payment records
|
|||||
| TMC SPEEDTMT Normalized: tmc speedtmt |
Device | TREACE MEDICAL CONCEPTS, INC. | $33.23 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $30.25 | 2 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $29.54 | 1 | 2025 |
Source payment records
|
|||||
| MATRIDERM Normalized: matriderm |
Device | Access Pro Medical, LLC | $26.94 | 1 | 2025 |
Source payment records
|
|||||
| Acumed Normalized: acumed |
Device | ACUMED LLC | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| Dynasplint Normalized: dynasplint |
Device | Dynasplint Systems Inc. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| Exparel Normalized: exparel |
Drug | Pacira Pharmaceuticals Incorporated | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| GII Normalized: gii |
Device | DePuy Synthes Sales Inc. | $21.79 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| ArdeoGraft Normalized: ardeograft |
Biological | Surgenex LLC | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| PelloGraft Normalized: pellograft |
Biological | Surgenex LLC | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| RenoGraft Normalized: renograft |
Biological | Surgenex LLC | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| SurGraft Normalized: surgraft |
Biological | Surgenex LLC | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| SurMatrix Normalized: surmatrix |
Biological | Surgenex LLC | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C. GRANUFOAM Normalized: v a c granufoam |
Device | Solventum Corporation | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO CLEANSE CHOICE Normalized: v a c veraflo cleanse choice |
Device | Solventum Corporation | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C.ULTA Normalized: v a c ulta |
Device | Solventum Corporation | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| CellerateRX Normalized: celleraterx |
Device | Sanara MedTech Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| Quickanchor Orthocord Normalized: quickanchor orthocord |
Device | DePuy Synthes Sales Inc. | $12.50 | 2 | 2025 |
Source payment records
|
|||||
| Gryphon Orthocord Normalized: gryphon orthocord |
Device | DePuy Synthes Sales Inc. | $6.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUZYRA nuzyra |
2025 | Nuzyra | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Paratek Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | NUZYRA open payments reported associated product |
CMS Open Payments — General Payments 24089 supporting records · 10216 recipient NPIs · example record 1181734338 |
Nuzyra · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 66 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 46 |
| Celecoxib | Celecoxib | 48 | 38 |
| Meloxicam | Meloxicam | 29 | 23 |
| Ssd | Silver Sulfadiazine | 23 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 13 |
| Cephalexin | Cephalexin | 17 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Nuzyra | Omadacycline Tosylate | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $136,439.88 · 119 records | TREACE MEDICAL CONCEPTS, INC. | ANCHORAGE, ASNIS, AUGMENT INJECTABLE, AXSOS, Acumed, ArdeoGraft, CITREFIX, COLLAGENASE SANTYL, CUT GUIDE, CellerateRX, DYNACORD, DYNATAPE, Dynasplint, Exparel, GAMMA, GII, GRAFIX PL, Gryphon Orthocord, HEALIX KNOTLESS PEEK, HOFFMANN, INBONE, INFINITY ADAPTIS, INTELLIS ADAPTIVESTIM, JOURNAVX, Kerecis GraftGuide, Kerecis SurgiClose, LAPIPLASTY, LAPIPLASTY SYSTEM 1, MATRIDERM, Miro3D, Monkey Bars, Monkey Rings, NUZYRA, ORTHOLOC 3DI, PERCUPLASTY TRAY, PREVENA, PROSTEP, PROSTEP MICA, PURAPLY WOUND MATRIX, PelloGraft, Portfolio, QUTENZA, Quickanchor Orthocord, RENASYS TOUCH, RenoGraft, Restrata Wound Matrix, STRAVIX, SurGraft, SurMatrix, T2, TMC NANOPLASTY SYSTEM, TMC SPEEDTMT, TREMFYA, V.A.C. GRANUFOAM, V.A.C. VERAFLO CLEANSE CHOICE, V.A.C.ULTA, VARIAX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuzyra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Paratek Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error